Golotimod hydrochloride SCV 07 hydrochloride; Gamma-D-glutamyl-L-tryptophan hydrochloride|西域试剂

Golotimod hydrochloride SCV 07 hydrochloride; Gamma-D-glutamyl-L-tryptophan hydrochloride,99.79%

产品编号：Bellancom-14743B| 分子式：C₁₆H₂₀ClN₃O₅| 分子量：369.80

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-14743B	￥650.00	杭州北京（现货）
Bellancom-14743B	￥1000.00	杭州北京（现货）
Bellancom-14743B	￥2500.00	杭州北京（现货）
Bellancom-14743B	￥3500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Golotimod hydrochloride SCV 07 hydrochloride; Gamma-D-glutamyl-L-tryptophan hydrochloride

产品介绍

Golotimod (SCV 07) hydrochloride 一种具有抗菌活性的免疫调节肽，可显著提高抗结核研究的功效，刺激胸腺和脾细胞增殖，并改善巨噬细胞功能。Golotimod hydrochloride 抑制 STAT3 信号传导并调节接受放疗或放疗与顺铂联合用药的动物模型中口腔粘膜炎的持续时间和严重程度。Golotimod hydrochloride 具有用于研究复发性生殖器单纯疱疹病毒 2 型 (HSV-2) 的潜力。

生物活性

Golotimod hydrochloride (SCV 07 hydrochloride), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod hydrochloride (SCV 07 hydrochloride) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod hydrochloride (SCV 07 hydrochloride) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2).

体外研究

体内研究

Golotimod (SCV-07) hydrochloride (oral gavage or subcutaneous injection, 100 μg/kg, 5 days) reduces experimental recurrent genital HSV-2 disease by oral administration, more importantly, oral SCV07 after fasting shows a greater reduction in incidence and severity than SCV-07 without fasting in female hartley guinea pigs.
Golotimod (SCV-07) hydrochloride (subcutaneous injection, once or twice a day from days 1 to 20, 100 μg/kg) can reduce the severity and duration of acute and split radiation-induced oral mucositis (OM) and short the duration of ulcerative OM in male LVG golden Syrian Hamsters.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female Hartley guinea pigs (250-300 g) infected HSV-2
Dosage:	100 μg/kg
Administration:	Oral gavage or subcutaneous injection; 5 days
Result:	Reduced incidence of lesions from 55% (one week before treatment) to only 18% by oral administration, and showed no significant reduction in disease by subcutaneous injection of SCV-07.

Animal Model:	Male LVG golden Syrian Hamsters weighing approximately 80 g with radiation-induced mucositis
Dosage:	10, 100 μg/kg or 1 mg/kg
Administration:	Subcutaneous injection; once or twice a day from days 1 to 20
Result:	Showed a peak mucositis of 3.0 on day 18 in the control group compared to only 2.2 in the test group, and the mucositis score in the SCV-07 treated hamsters was only 6.3% compared to 28.1% in the control group at dose of 100 μg/kg. Significantly decreased the severity and duration of oral mucositis (OM) at dose of 10 μg/kg, 100 μg/kg or 1 mg/kg.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female Hartley guinea pigs (250-300 g) infected HSV-2
Dosage:	100 μg/kg
Administration:	Oral gavage or subcutaneous injection; 5 days
Result:	Reduced incidence of lesions from 55% (one week before treatment) to only 18% by oral administration, and showed no significant reduction in disease by subcutaneous injection of SCV-07.

Animal Model:	Male LVG golden Syrian Hamsters weighing approximately 80 g with radiation-induced mucositis
Dosage:	10, 100 μg/kg or 1 mg/kg
Administration:	Subcutaneous injection; once or twice a day from days 1 to 20
Result:	Showed a peak mucositis of 3.0 on day 18 in the control group compared to only 2.2 in the test group, and the mucositis score in the SCV-07 treated hamsters was only 6.3% compared to 28.1% in the control group at dose of 100 μg/kg. Significantly decreased the severity and duration of oral mucositis (OM) at dose of 10 μg/kg, 100 μg/kg or 1 mg/kg.

性状

Solid

溶解性数据

In Vitro:

H₂O : 150 mg/mL (405.62 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.7042 mL	13.5208 mL	27.0416 mL
5 mM	0.5408 mL	2.7042 mL	5.4083 mL
10 mM	0.2704 mL	1.3521 mL	2.7042 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶